Infectious & Post-Infectious Disease: Lyme Disease, Long COVID & Chronic Viral Illness

Introduction

Infectious and post-infectious diseases represent one of the most challenging and underappreciated frontiers in modern medicine. Conditions like chronic Lyme disease, Long COVID, and Epstein-Barr virus (EBV) reactivation share a common and frustrating clinical profile: they follow an acute infection, persist long after the pathogen is theoretically cleared, and produce a constellation of symptoms — fatigue, pain, cognitive impairment, immune dysregulation, and neurological dysfunction — that conventional medicine struggles to explain or treat.

What unites these conditions is a shared biological architecture: persistent immune activation, neuroinflammation, mitochondrial dysfunction, gut dysbiosis, and — in many cases — ongoing low-level pathogen persistence or reactivation. Understanding this architecture is the key to developing rational, integrative therapeutic strategies that address root causes rather than managing symptoms in isolation.

Part I: Lyme Disease & Chronic Lyme

Acute Lyme Disease

Lyme disease is caused by the spirochete bacterium Borrelia burgdorferi, transmitted primarily by Ixodes ticks. Acute Lyme presents with the characteristic erythema migrans (bull's-eye) rash in 70–80% of cases, alongside flu-like symptoms, fatigue, and musculoskeletal pain. Early antibiotic treatment (doxycycline, amoxicillin) is highly effective when initiated promptly.

Post-Treatment Lyme Disease Syndrome (PTLDS) & Chronic Lyme

Approximately 10–20% of patients treated for Lyme disease develop Post-Treatment Lyme Disease Syndrome (PTLDS) — persistent symptoms lasting months to years after antibiotic completion. Symptoms include debilitating fatigue, musculoskeletal pain, cognitive impairment ("Lyme brain"), neuropathy, sleep disturbance, and mood disorders.

The mechanisms underlying PTLDS are multifactorial and contested:

• Persistent bacterial remnants — Borrelia can form antibiotic-tolerant persister cells and biofilms that evade standard antibiotic treatment and maintain immune activation
• Molecular mimicry — Borrelia antigens trigger cross-reactive autoimmune responses against host tissues, particularly neural and joint tissue
• Neuroinflammation — microglial activation persisting after bacterial clearance drives ongoing CNS symptoms including cognitive impairment, fatigue, and pain
• Mitochondrial dysfunction — Borrelia toxins and the inflammatory response impair mitochondrial function, driving fatigue and cellular energy deficits (Seyfried et al.)
• Gut dysbiosis — antibiotic treatment profoundly disrupts the gut microbiome, amplifying systemic inflammation and impairing immune regulation (see our Gut Microbiome guide)
• Co-infections — Borrelia is frequently transmitted alongside Bartonella, Babesia, Anaplasma, and Ehrlichia, which complicate treatment and perpetuate immune dysregulation

Makis et al. have highlighted the role of persistent immune activation and biofilm formation in chronic Lyme, noting that antiparasitic and antimicrobial agents with biofilm-disrupting properties offer therapeutic potential beyond standard antibiotics.

Lyme Neuroborreliosis

When Borrelia disseminates to the CNS — Lyme neuroborreliosis — it produces meningitis, cranial nerve palsies, radiculopathy, and encephalopathy. Chronic neuroborreliosis involves persistent microglial activation, BBB disruption, and neuroinflammatory damage that can persist long after bacterial clearance, producing a clinical picture overlapping with MS, fibromyalgia, and ME-CFS.

Part II: Long COVID

The Scale of the Problem

Long COVID — defined as symptoms persisting beyond 12 weeks after acute SARS-CoV-2 infection — affects an estimated 65 million people globally, representing one of the largest post-infectious disease burdens in history. Symptoms are diverse and multisystemic: fatigue (the most common symptom), cognitive impairment ("brain fog"), dyspnea, chest pain, palpitations, post-exertional malaise (PEM), neuropathy, sleep disturbance, anxiety, depression, and autonomic dysfunction (POTS).

Mechanisms of Long COVID

Long COVID is now understood to involve multiple overlapping pathological mechanisms:

• Viral persistence — SARS-CoV-2 RNA and protein have been detected in multiple tissues (gut, brain, lymph nodes, blood) months to years after acute infection, maintaining immune activation and inflammation
• Immune dysregulation — persistent T-cell exhaustion, NK cell dysfunction, elevated inflammatory cytokines (IL-6, TNF-α, IL-1β), and autoantibody production (against G-protein coupled receptors, ACE2, and other targets)
• Microbiome disruption — SARS-CoV-2 profoundly disrupts the gut microbiome; gut dysbiosis persists in Long COVID and correlates with symptom severity; reduced Akkermansia muciniphila and Faecalibacterium prausnitzii are consistent findings
• Neuroinflammation — microglial activation in the brain drives cognitive impairment, fatigue, and mood disorders; SARS-CoV-2 can directly infect CNS cells and activate microglia via ACE2 receptors and spike protein-mediated TLR4 signaling
• Mitochondrial dysfunction — SARS-CoV-2 directly impairs mitochondrial function; persistent mitochondrial dysfunction drives fatigue, PEM, and cellular energy deficits (Seyfried et al.)
• Endothelial dysfunction and microclotting — spike protein-mediated endothelial activation, platelet aggregation, and fibrin microclot formation impair tissue oxygenation and contribute to multisystem symptoms
• EBV reactivation — SARS-CoV-2 infection frequently triggers EBV reactivation, which may independently drive Long COVID symptoms
• Mast cell activation — SARS-CoV-2 activates mast cells, contributing to histamine-driven symptoms and neuroinflammation

Andries et al. have highlighted the gut-immune axis as a critical driver of Long COVID persistence, noting that gut viral reservoir and dysbiosis maintain systemic immune activation long after respiratory clearance.

Long COVID & the Autonomic Nervous System

Autonomic dysfunction — particularly POTS (Postural Orthostatic Tachycardia Syndrome) — is among the most debilitating Long COVID manifestations. Mechanisms include autoantibodies against adrenergic and muscarinic receptors, small fiber neuropathy, and sympathetic nervous system hyperactivation driven by neuroinflammation. The overlap with mast cell activation syndrome is significant — MCAS, POTS, and hypermobile EDS frequently co-occur in Long COVID patients.

Part III: EBV & Chronic Viral Illness

Epstein-Barr Virus (EBV)

EBV — the causative agent of infectious mononucleosis — infects over 95% of adults globally and establishes lifelong latency in B lymphocytes. EBV reactivation — triggered by immune suppression, chronic stress, nutritional deficiencies, or co-infections — is increasingly recognized as a driver of chronic fatigue, immune dysregulation, and neurological symptoms.

EBV has been implicated as a trigger or driver of multiple chronic conditions:

• Multiple Sclerosis — landmark 2022 Harvard study demonstrated that EBV infection is a necessary precursor to MS in virtually all cases, with EBV-infected B cells triggering cross-reactive autoimmune responses against myelin (see our MS/NMOSD article)
• Autoimmune diseases — EBV molecular mimicry drives autoimmune responses in lupus, rheumatoid arthritis, Sjögren's syndrome, and IBD (see our Autoimmune Disease article)
• ME-CFS — EBV reactivation is a common trigger for ME-CFS; elevated EBV antibody titers are found in a significant proportion of ME-CFS patients
• Lymphoma — EBV drives Burkitt lymphoma, Hodgkin lymphoma, and other B-cell malignancies via oncogenic transformation
• Long COVID amplification — EBV reactivation triggered by SARS-CoV-2 may independently contribute to Long COVID symptoms

Other Chronic Viral Illnesses

• HHV-6 (Human Herpesvirus 6) — reactivation associated with ME-CFS, neurological symptoms, and immune dysregulation; particularly relevant in post-infectious fatigue syndromes
• Cytomegalovirus (CMV) — chronic CMV reactivation drives immune senescence and systemic inflammation, particularly in immunocompromised individuals
• Enteroviruses — persistent enteroviral infection in gut and muscle tissue is implicated in ME-CFS and post-viral fatigue
• HSV-1 — reactivation in the brain implicated in Alzheimer's disease and neurological post-infectious syndromes (see our Neurological Health article)

Part IV: The Shared Pathological Architecture

Lyme disease, Long COVID, and chronic viral illness share a unified pathological framework:

• Persistent immune activation — ongoing cytokine elevation (IL-6, TNF-α, IL-1β, IFN-γ) maintaining systemic and neuroinflammation
• Neuroinflammation — microglial activation driving fatigue, cognitive impairment, pain, and mood disorders
• Mitochondrial dysfunction — impaired cellular energy metabolism driving fatigue and post-exertional malaise (Seyfried et al.)
• Gut dysbiosis — antibiotic treatment (Lyme) and direct viral disruption (COVID, EBV) impair the gut microbiome, amplifying systemic inflammation
• Autoimmune cross-reactivity — molecular mimicry triggering self-directed immune responses
• ECS dysregulation — reduced endocannabinoid tone impairing immune regulation and neuroinflammation resolution (see our ECS guide)
• Mast cell activation — pathogen-triggered mast cell activation amplifying histamine-driven inflammation and neuroinflammation

Part V: Integrative Approaches

Low Dose Naltrexone (LDN)

LDN is one of the most clinically relevant agents for post-infectious conditions. Its TLR4 antagonism directly suppresses the microglial activation and macrophage-driven inflammation that perpetuates post-infectious neuroinflammation. Endorphin upregulation supports immune homeostasis and reduces fatigue. Cairns et al. have documented LDN's efficacy in ME-CFS, fibromyalgia, and post-infectious fatigue syndromes, with improvements in fatigue, cognitive function, pain, and quality of life. Andries et al. have highlighted LDN's gut-immune axis modulation as particularly relevant in Long COVID and post-Lyme conditions where gut dysbiosis drives ongoing immune activation.

Ivermectin

Ivermectin's relevance to post-infectious disease is multifaceted. Its antiviral properties — inhibiting viral replication via importin α/β nuclear transport blockade — are relevant to Long COVID viral persistence and EBV/HHV-6 reactivation. Its anti-inflammatory mechanisms (NF-κB inhibition, NLRP3 suppression) address the persistent immune activation driving post-infectious symptoms. Its antiparasitic action is relevant to Lyme co-infections including Babesia. Makis et al. have highlighted ivermectin's broad antiviral and anti-inflammatory potential in post-infectious conditions, with clinical observations supporting its use in Long COVID.

Mebendazole & Niclosamide

Mebendazole's biofilm-disrupting properties — via tubulin inhibition — are relevant to Borrelia biofilm formation in chronic Lyme. Niclosamide's STAT3 inhibition addresses the persistent IL-6/STAT3 signaling driving immune dysregulation in Long COVID and post-viral illness. Seyyedabadi et al. have highlighted STAT3 as a key driver of post-infectious immune dysregulation and a high-value therapeutic target.

DMSO

DMSO's membrane-penetrating properties enhance delivery of antimicrobial and anti-inflammatory agents into biofilm-protected bacterial communities in chronic Lyme. Its free radical scavenging reduces oxidative stress driving mitochondrial dysfunction in post-infectious fatigue. Cairns et al. have noted DMSO's potential as an adjunct in chronic infectious and post-infectious conditions.

CBD & THC

The endocannabinoid system plays a critical role in immune regulation, neuroinflammation resolution, and mitochondrial protection — all impaired in post-infectious conditions. CBD provides CB2-mediated immune modulation reducing persistent cytokine elevation; microglial suppression addressing neuroinflammatory cognitive and fatigue symptoms; FAAH inhibition increasing anandamide supporting stress resilience and sleep; and mitochondrial protection reducing oxidative stress. THC provides CB1-mediated pain relief, sleep improvement, appetite support, and nausea reduction — all relevant in post-infectious debilitation. For Long COVID mast cell activation, CBD's mast cell-stabilizing properties via CB2 and PPAR-α are particularly relevant.

Antiviral & Antimicrobial Botanicals

• Andrographis paniculata — potent antiviral and anti-inflammatory herb; inhibits NF-κB and viral replication; clinical evidence in acute viral illness and post-viral fatigue; particularly relevant in Long COVID and EBV reactivation
• Cat's Claw (Uncaria tomentosa) — anti-Borrelia activity, NF-κB inhibition, and immune modulation; widely used in Lyme disease protocols
• Japanese Knotweed (Resveratrol source / Polygonum cuspidatum) — anti-Borrelia activity, SIRT1 activation, NF-κB suppression, and anti-neuroinflammatory effects; a cornerstone of the Buhner Lyme protocol
• Astragalus membranaceus — adaptogenic immune modulator; antiviral properties against EBV and enteroviruses; supports NK cell and T-cell function
• Olive Leaf Extract (Oleuropein) — broad-spectrum antimicrobial and antiviral; inhibits viral replication and reduces inflammatory cytokines
• Monolaurin — derived from lauric acid (coconut oil); disrupts lipid-enveloped viral membranes (EBV, CMV, HHV-6, SARS-CoV-2); antimicrobial against Borrelia
• Berberine — antimicrobial against Borrelia persister cells, antiviral, gut microbiome restoration; addresses multiple post-infectious drivers simultaneously
• N-Acetyl Cysteine (NAC) — glutathione precursor; reduces oxidative stress, supports mitochondrial function, mucolytic properties relevant in Long COVID respiratory symptoms, and antiviral via glutathione-mediated immune support

Mitochondrial Support

Given Seyfried et al.'s framework identifying mitochondrial dysfunction as a primary driver of post-infectious fatigue and cellular dysfunction, mitochondrial support is foundational:

• CoQ10 (200–400mg/day) — essential mitochondrial electron transport chain cofactor; reduced in post-infectious fatigue
• NAD+ precursors (NMN/NR, 500mg/day) — restore NAD+ levels depleted by viral infection and chronic inflammation; support mitochondrial biogenesis
• D-Ribose (5g 3x/day) — mitochondrial ATP synthesis substrate; clinical evidence in ME-CFS and post-viral fatigue
• Magnesium malate (400–600mg/day) — mitochondrial cofactor; malate supports Krebs cycle function
• ALA (600mg/day) — mitochondrial antioxidant; reduces oxidative stress in post-infectious neural and muscle tissue

Gut Restoration

Restoring gut microbiome integrity is essential in all post-infectious conditions — particularly post-Lyme (antibiotic-disrupted microbiome) and Long COVID (viral gut disruption). A comprehensive gut restoration protocol including multi-strain probiotics, prebiotics, L-glutamine, zinc carnosine, and colostrum addresses the gut dysbiosis perpetuating systemic immune activation. See our Gut Microbiome guide for a full protocol.

Integrative Post-Infectious Protocol

• LDN (1.5–4.5mg/day) — microglial suppression, immune homeostasis, fatigue reduction
• Ivermectin — antiviral, anti-inflammatory, anti-Babesia (under medical supervision)
• Niclosamide — STAT3/IL-6 axis suppression (under medical supervision)
• CBD (50–150mg/day) + low-dose THC — immune modulation, neuroinflammation, sleep, pain
• Andrographis (400mg 2x/day) — antiviral, NF-κB suppression
• Cat's Claw (700mg 2x/day) — anti-Borrelia, immune modulation (Lyme-specific)
• Japanese Knotweed / Resveratrol — anti-Borrelia, SIRT1, neuroinflammation
• Monolaurin (1800–3600mg/day) — antiviral membrane disruption
• NAC (600–1200mg/day) — glutathione support, antiviral, mitochondrial protection
• CoQ10 (200–400mg/day) + NMN/NR (500mg/day) — mitochondrial restoration
• D-Ribose (5g 3x/day) — ATP synthesis support
• Berberine (500mg 2–3x/day) — antimicrobial, gut restoration, AMPK activation
• Gut restoration protocol — probiotics, prebiotics, L-glutamine, zinc carnosine
• Mast cell stabilization — quercetin, PEA, vitamin C (especially in Long COVID/MCAS overlap)
• Pacing and graded activity — essential in ME-CFS/Long COVID to avoid post-exertional malaise

This article is for educational purposes only and does not constitute medical advice. Post-infectious conditions are complex and require individualized care from qualified healthcare providers.

Key References

• Makis, W. et al. — Ivermectin: antiviral and anti-inflammatory potential in Long COVID and post-infectious disease.
• Cairns, D.M. et al. — LDN in post-infectious fatigue, ME-CFS, and neuroinflammatory conditions.
• Andries, K. et al. — Gut-immune axis in Long COVID and post-infectious immune dysregulation.
• Seyyedabadi, B. et al. — STAT3/IL-6 signaling in post-infectious immune dysregulation.
• Noori, S. et al. — Natural antimicrobial and anti-inflammatory compounds in post-infectious disease.
• Seyfried, T.N. et al. — Mitochondrial dysfunction in post-infectious fatigue and ME-CFS.